Compared with MS, the levels of 36 analytes were significantly increased in MOGAD patients, which are namely IL-8, SDF-1α, MCP-1, GRO-α, IL-18, MIP-1β, Fractalkine, HGF, IP-10, SCF, VEGF-A, BAFF, IL-7, TWEAK, MIP-3α, M-CSF, CD40L, MMP-1, IL-27, MIG, LIF, MIP-1α, IL-17A, IL-23, TNF-β, IL-1α, IL-6, IL-21, IL-5, MDC, IL-9, FGF-2, Eotaxin-3, IL-10, Eotaxin-2, IL-31 (Figures 1A, B; Supplementary Figure 1). This evidence concerns the gene CXCL1 and myeloid sarcoma.